Literature DB >> 21849500

An artificial antigen-presenting cell with paracrine delivery of IL-2 impacts the magnitude and direction of the T cell response.

Erin R Steenblock1, Tarek Fadel, Michael Labowsky, Jordan S Pober, Tarek M Fahmy.   

Abstract

Artificial antigen-presenting cells (aAPCs) are an emerging technology to induce therapeutic cellular immunity without the need for autologous antigen-presenting cells (APCs). To fully replace natural APCs, an optimized aAPC must present antigen (signal 1), provide costimulation (signal 2), and release cytokine (signal 3). Here we demonstrate that the spatial and temporal characteristics of paracrine release of IL-2 from biodegradable polymer aAPCs (now termed paAPCs) can significantly alter the balance in the activation and proliferation of CD8+ and CD4+ T cells. Paracrine delivery of IL-2 upon T cell contact with paAPCs induces significant IL-2 accumulation in the synaptic contact region. This accumulation increases CD25 (the inducible IL-2 Rα chain) on responding T cells and increases proliferation of CD8+ T cells in vitro to levels 10 times that observed with equivalent amounts of bulk IL-2. These CD8+ T cell responses critically depend upon close contact of T cells and the paAPCs and require sustained release of low levels of IL-2. The same conditions promote activation-induced cell death in CD4+ T cells. These findings provide insight into the response of T cell subsets to paracrine IL-2.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21849500      PMCID: PMC3186438          DOI: 10.1074/jbc.M111.276329

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses.

Authors:  Kathryn E Foulds; Lauren A Zenewicz; Devon J Shedlock; Jiu Jiang; Amy E Troy; Hao Shen
Journal:  J Immunol       Date:  2002-02-15       Impact factor: 5.422

Review 2.  Spinning molecular immunology into successful immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Immunol       Date:  2002-04       Impact factor: 53.106

3.  Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity.

Authors:  Howard L Kaufman; Ken Flanagan; Christopher S D Lee; Donato J Perretta; Heidi Horig
Journal:  Vaccine       Date:  2002-03-15       Impact factor: 3.641

4.  Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates.

Authors:  Jason Park; Thomas Mattessich; Steven M Jay; Atu Agawu; W Mark Saltzman; Tarek M Fahmy
Journal:  J Control Release       Date:  2011-06-24       Impact factor: 9.776

5.  In situ vaccination against a non-immunogenic tumour using intratumoural injections of liposomal interleukin 2.

Authors:  M E Neville; R J Robb; M C Popescu
Journal:  Cytokine       Date:  2001-12-21       Impact factor: 3.861

6.  A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo.

Authors:  A B Shanafelt; Y Lin; M C Shanafelt; C P Forte; N Dubois-Stringfellow; C Carter; J A Gibbons; S L Cheng; K A Delaria; R Fleischer; J M Greve; R Gundel; K Harris; R Kelly; B Koh; Y Li; L Lantz; P Mak; L Neyer; M J Plym; S Roczniak; D Serban; J Thrift; L Tsuchiyama; M Wetzel; M Wong; A Zolotorev
Journal:  Nat Biotechnol       Date:  2000-11       Impact factor: 54.908

7.  IL-2 mediates adjuvant effect of dendritic cells.

Authors:  Francesca Granucci; Daniel M Andrews; Mariapia A Degli-Esposti; Paola Ricciardi-Castagnoli
Journal:  Trends Immunol       Date:  2002-04       Impact factor: 16.687

8.  Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys.

Authors:  D H Barouch; A Craiu; M J Kuroda; J E Schmitz; X X Zheng; S Santra; J D Frost; G R Krivulka; M A Lifton; C L Crabbs; G Heidecker; H C Perry; M E Davies; H Xie; C E Nickerson; T D Steenbeke; C I Lord; D C Montefiori; T B Strom; J W Shiver; M G Lewis; N L Letvin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

9.  Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis.

Authors:  Protul Shrikant; Matthew F Mescher
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

10.  A significant enhancement of therapeutic effect against hepatic metastases of M5076 in mice by a liposomal interleukin-2 (mixture).

Authors:  Eri Kanaoka; Kouji Takahashi; Takayoshi Yoshikawa; Hiroaki Jizomoto; Yoshitaka Nishihara; Naomi Uchida; Ryuji Maekawa; Koichiro Hirano
Journal:  J Control Release       Date:  2002-08-21       Impact factor: 9.776

View more
  51 in total

1.  Cytokine Secreting Microparticles Engineer the Fate and the Effector Functions of T-Cells.

Authors:  Fatemeh S Majedi; Mohammad Mahdi Hasani-Sadrabadi; Yoko Kidani; Timothy J Thauland; Alireza Moshaverinia; Manish J Butte; Steven J Bensinger; Louis-S Bouchard
Journal:  Adv Mater       Date:  2018-01-08       Impact factor: 30.849

2.  Immunomodulatory nanoparticles ameliorate disease in the Leishmania (Viannia) panamensis mouse model.

Authors:  Alyssa L Siefert; Allison Ehrlich; María Jesús Corral; Karen Goldsmith-Pestana; Diane McMahon-Pratt; Tarek M Fahmy
Journal:  Biomaterials       Date:  2016-09-06       Impact factor: 12.479

Review 3.  Micro and nanoparticle drug delivery systems for preventing allotransplant rejection.

Authors:  James D Fisher; Abhinav P Acharya; Steven R Little
Journal:  Clin Immunol       Date:  2015-05-01       Impact factor: 3.969

4.  Suppression of Murine Lupus by CD4+ and CD8+ Treg Cells Induced by T Cell-Targeted Nanoparticles Loaded With Interleukin-2 and Transforming Growth Factor β.

Authors:  David A Horwitz; Sean Bickerton; Michael Koss; Tarek M Fahmy; Antonio La Cava
Journal:  Arthritis Rheumatol       Date:  2019-03-05       Impact factor: 10.995

Review 5.  Biomimetic and synthetic interfaces to tune immune responses.

Authors:  Anusha Garapaty; Julie A Champion
Journal:  Biointerphases       Date:  2015-09-15       Impact factor: 2.456

Review 6.  Surface engineering for lymphocyte programming.

Authors:  Elana Ben-Akiva; Randall A Meyer; David R Wilson; Jordan J Green
Journal:  Adv Drug Deliv Rev       Date:  2017-05-10       Impact factor: 15.470

Review 7.  Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.

Authors:  Wenji Sun; Priyanka B Subrahmanyam; James E East; Tonya J Webb
Journal:  J Interferon Cytokine Res       Date:  2012-10-10       Impact factor: 2.607

Review 8.  Nanoengineering approaches to the design of artificial antigen-presenting cells.

Authors:  Joel C Sunshine; Jordan J Green
Journal:  Nanomedicine (Lond)       Date:  2013-07       Impact factor: 5.307

9.  Configuration-dependent Presentation of Multivalent IL-15:IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity.

Authors:  Enping Hong; Ilana M Usiskin; Cristina Bergamaschi; Douglas J Hanlon; Richard L Edelson; Sune Justesen; George N Pavlakis; Richard A Flavell; Tarek M Fahmy
Journal:  J Biol Chem       Date:  2015-12-30       Impact factor: 5.157

10.  Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells.

Authors:  Joel C Sunshine; Karlo Perica; Jonathan P Schneck; Jordan J Green
Journal:  Biomaterials       Date:  2013-10-05       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.